Kaitlyn M Morabito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4717268/publications.pdf

Version: 2024-02-01

30 papers

6,570 citations

331538 21 h-index 477173 29 g-index

31 all docs

31 docs citations

31 times ranked 11948 citing authors

#	Article	IF	CITATIONS
1	An mRNA Vaccine against SARS-CoV-2 â€" Preliminary Report. New England Journal of Medicine, 2020, 383, 1920-1931.	13.9	2,719
2	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	13.7	1,153
3	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	13.9	936
4	Rapid development of a DNA vaccine for Zika virus. Science, 2016, 354, 237-240.	6.0	348
5	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet, The, 2018, 391, 552-562.	6.3	235
6	A proof of concept for structure-based vaccine design targeting RSV in humans. Science, 2019, 365, 505-509.	6.0	207
7	A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nature Communications, 2017, 8, 676.	5.8	125
8	Immunological Lessons from Respiratory Syncytial Virus Vaccine Development. Immunity, 2019, 51, 429-442.	6.6	99
9	Quantitative and Qualitative Deficits in Neonatal Lung-Migratory Dendritic Cells Impact the Generation of the CD8+ T Cell Response. PLoS Pathogens, 2014, 10, e1003934.	2.1	78
10	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity, 2021, 54, 1869-1882.e6.	6.6	59
11	Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses. ACS Biomaterials Science and Engineering, 2016, 2, 2324-2332.	2.6	50
12	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. Science Advances, 2020, 6, eaba5068.	4.7	50
13	Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjugate Chemistry, 2016, 27, 2372-2385.	1.8	44
14	Determinants of early life immune responses to RSV infection. Current Opinion in Virology, 2016, 16, 151-157.	2.6	40
15	Zika Virus Vaccine Development. Journal of Infectious Diseases, 2017, 216, S957-S963.	1.9	38
16	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respiratory Medicine, the, 2021, 9, 1111-1120.	5.2	38
17	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity, 2021, 54, 769-780.e6.	6.6	37
18	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. Frontiers in Immunology, 2020, 11, 842.	2.2	36

#	Article	IF	CITATIONS
19	Memory Inflation Drives Tissue-Resident Memory CD8+ T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus. Frontiers in Immunology, 2018, 9, 1861.	2.2	31
20	DNA vaccination before conception protects Zika virus–exposed pregnant macaques against prolonged viremia and improves fetal outcomes. Science Translational Medicine, 2019, 11, .	5.8	31
21	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Science Translational Medicine, 2020, 12, .	5.8	30
22	Epitope-Specific Serological Assays for RSV: Conformation Matters. Vaccines, 2019, 7, 23.	2.1	26
23	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. Frontiers in Immunology, 2021, 12, 772864.	2.2	21
24	Pulmonary Dendritic Cell Subsets Shape the Respiratory Syncytial Virus–Specific CD8+ T Cell Immunodominance Hierarchy in Neonates. Journal of Immunology, 2017, 198, 394-403.	0.4	20
25	A Numerically Subdominant CD8 T Cell Response to Matrix Protein of Respiratory Syncytial Virus Controls Infection with Limited Immunopathology. PLoS Pathogens, 2016, 12, e1005486.	2.1	18
26	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. Science Translational Medicine, 2022, 14, .	5.8	7
27	Limited Flavivirus Cross-Reactive Antibody Responses Elicited by a Zika Virus Deoxyribonucleic Acid Vaccine Candidate in Humans. Journal of Infectious Diseases, 2021, 224, 1550-1555.	1.9	5
28	Recurrent respiratory syncytial virus infection in a CD14 deficient patient. Journal of Infectious Diseases, 2022, , .	1.9	5
29	Phenotype and Hierarchy of Two Transgenic T Cell Lines Targeting the Respiratory Syncytial Virus KdM282-90 Epitope Is Transfer Dose-Dependent. PLoS ONE, 2016, 11, e0146781.	1.1	4
30	Vaccination Against Respiratory Syncytial Virus. , 2020, , 665-676.		0